Search results for: Precision Medicine
Filter search results
OHE Welcomes Charlesworth and Mays to its Editorial Board
14 January 2014
…January 2014, Anita Charlesworth, Chief Economist at the Nuffield Trust, and Professor Nicholas Mays, London School of Hygiene and Tropical Medicine, joined the Board. Composed of academics and thought leaders…
Bengt Jönsson Honoured for Contribution to Health Economics
6 August 2014
…The chapter contributed by OHE’s Adrian Towse[2] discusses Bengt’s observations in a 2011 publication[3] about the role of relative effectiveness research (RE) in the European medicines market. To ensure value…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…on medicines. The provisions in the Act relating to pharmaceutical coverage and reimbursement are complex, and include inflation rebates, price negotiations for some Medicare drugs (for the first time), and…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
…integral to multiple myeloma treatment. Wider adoption of On-Body Injectors can help overcome formulation and delivery challenges, unlocking the full value of biologics and other anti-cancer medicines. This contract research…
A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
1 July 2020
…economic value of new medicines between consumers (payers) and developers (life science… This paper presents a supply and demand model of pharmaceutical markets to analyse the relationship between the value…
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
…new treatments for rare and chronically disabling or life-threatening diseases. Marketing authorisation granted to OMPs, however, is only the first step; patients have access to medicines once reimbursement or health…
Prescribing, Budgets and Fundholding in General Practice
10 January 1997
…practice was a particular focus of attention. The preparatory White Paper (CM 555, 1989) noted that prescription medicines formed the largest single expenditure item for the Family Practitioner Services and…
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
12 June 2025
…pharmaceutical industry (for example, via industry clawback schemes that cap medicines expenditure overall, like the voluntary scheme [VPAG] in the UK). Furthermore, the potential for higher revenue outside the US…
End of Life Treatments, Societal Values, and ‘Overall’ Preference
12 February 2019
…life-extending end of life treatments. His presentation summarised a comprehensive review of the stated preference literature, published last year in Social Science & Medicine. The second half of the presentation…